Roche Holding AG Bearer Shares RHHBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RHHBF is a good fit for your portfolio.
News
-
Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study
-
Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion
-
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk's Ozempic
-
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments — Update
-
Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI
-
Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal
-
Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment
-
Trending: Roche to Buy Telavant From Roivant and Pfizer
Trading Information
- Previous Close Price
- $304.50
- Day Range
- $307.50–307.50
- 52-Week Range
- $262.50–409.50
- Bid/Ask
- $294.00 / $331.60
- Market Cap
- $245.59 Bil
- Volume/Avg
- 3 / 101
Key Statistics
- Price/Earnings (Normalized)
- 14.75
- Price/Sales
- 3.77
- Dividend Yield
- 3.33%
- Dividend Yield (Forward)
- 3.59%
- Total Yield
- 3.33%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 103,613
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RHHBF
|
MRK
|
REGN
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.75 | 34.38 | 18.46 |
Price/Book Value | 8.33 | 6.53 | 3.59 |
Price/Sales | 3.77 | 4.56 | 7.13 |
Price/Cash Flow | 12.72 | 13.62 | 19.16 |
Price/Earnings
RHHBF
MRK
REGN
Financial Strength
|
Metric
|
RHHBF
|
MRK
|
REGN
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.83 | 4.31 |
Current Ratio | 1.18 | 1.38 | 5.18 |
Interest Coverage | 17.42 | 7.59 | 55.91 |
Quick Ratio
RHHBF
MRK
REGN
Profitability
|
Metric
|
RHHBF
|
MRK
|
REGN
|
|---|---|---|---|
Return on Assets (Normalized) | 17.37% | 7.38% | 17.12% |
Return on Equity (Normalized) | 56.49% | 18.18% | 22.00% |
Return on Invested Capital (Normalized) | 27.41% | 10.92% | 18.50% |
Return on Assets
RHHBF
MRK
REGN
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
LLY
| Eli Lilly and Co | Llm | $558.3 Bil | |
JNJ
| Johnson & Johnson | Qrwx | $381.7 Bil | |
MRK
| Merck & Co Inc | Wbh | $269.2 Bil | |
ABBV
| AbbVie Inc | Nqfzqjm | $255.2 Bil | |
RHHBY
| Roche Holding AG ADR | Ljycy | $231.4 Bil | |
NVS
| Novartis AG ADR | Nmy | $200.2 Bil | |
AZN
| AstraZeneca PLC ADR | Cpz | $199.6 Bil | |
PFE
| Pfizer Inc | Zvl | $164.3 Bil | |
AMGN
| Amgen Inc | Bnjym | $145.0 Bil | |
SNY
| Sanofi SA ADR | Ylsw | $118.9 Bil |